# Vivace Therapeutics Appoints Craig Gibbs as President and CEO

Vivace Therapeutics has named Craig Gibbs, Ph.D., as its new president and chief executive officer. The appointment comes as the company prepares to launch a Phase 3 clinical trial.

Gibbs will lead the company through this late-stage development push. The leadership change is effective immediately.

## Context

Vivace Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancer. A CEO appointment ahead of a pivotal Phase 3 trial is a common transition in the biotech industry. Companies often bring in executives with experience in late-stage development, regulatory strategy, and commercialization as they approach the final clinical hurdle before seeking marketing approval. The move signals the company’s intent to scale operations and prepare for potential regulatory interactions.

Source: [original report](https://www.fiercebiotech.com/biotech/chutes-ladders-vivace-adds-new-ceo-cbo-ahead-ph-3-trial)